Abstract
The proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, evolocumab, promotes regression of coronary atherosclerosis in statin-treated patients. It is unknown whether there are gender related differences in this treatment effect. GLAGOV compared the effects of treatment for 78 weeks
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.